查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1344452

慢性腎臟病治療市場：按治療、按最終用戶：2023-2032 年全球機會分析和產業預測

Chronic kidney disease treatment Market By Treatment (Drugs, Dialysis), By End User (Hospital, Dialysis Center, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 238 Pages | 商品交期: 2-3個工作天內

價格

2022年慢性腎臟病治療市值為320億美元，預計2023年至2032年複合年增長率為4%，到2032年達到479億美元。

慢性腎臟病治療市場-IMG1

慢性腎臟病 (CKD) 治療是指旨在管理和減緩腎臟損傷及其相關併發症進展的各種醫療幹預措施和策略。 CKD 是一種進行性疾病，腎臟逐漸失去過濾血液中廢物和多餘水分的能力。 CKD 治療的目標包括保留腎功能、控制症狀、預防或控制併發症以及改善 CKD 患者的整體生活品質。

治療方法包括改善生活方式（例如改變飲食和定期運動）、控制血壓的藥物治療和基礎疾病管理，以及貧血和骨病等併發症的治療。晚期幹預措施包括腎臟替代療法例如透析和腎移植。 治療計劃根據每個人的 CKD 階段、潛在疾病、共病和整體健康狀況量身定制。 定期監測、與醫療保健提供者密切合作以及遵守治療計劃對於優化 CKD 患者的預後和維持腎臟健康至關重要。

CKD 盛行率的增加是 CKD 治療市場的關鍵驅動因素。 由於多種因素，包括人口老化、糖尿病和高血壓等危險因素盛行率的增加以及認識和診斷的提高，慢性腎臟病的全球負擔正在穩步增加。 例如，人口老化是慢性腎臟病盛行率增加的一個主要因素。 隨著人口老化，罹患 CKD 的風險趨於增加。 根據世界衛生組織（WHO）2022年預測，到2050年，全球60歲及以上人口預計將達到20億，這將對包括CKD在內的與年齡相關的疾病的流行產生重大影響。

此外，糖尿病和高血壓等危險因子的日益普及正在加劇 CKD 的流行。 尤其是糖尿病，是 CKD 的主要原因。 國際糖尿病聯盟估計，2021年約有5.37億成年人患有糖尿病，到2030年這一數字將增加至6.43億，到2045年預計將增至7.83億。 這樣，與 CKD 高風險直接相關的病例正在推動市場成長。

目錄

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 促進因素
      • 慢性腎臟病治療的技術進步
      • 慢性腎臟病 (CKD) 盛行率不斷上升
    • 抑制因素
      • 慢性腎臟病治療費用高昂
    • 機會
      • 新興市場的成長機會
  • 新冠肺炎 (COVID-19) 市場影響分析

第 4 章慢性腎臟病治療市場：依治療分類

  • 摘要
  • 醫學
  • 透析治療

第 5 章慢性腎臟病藥物市場：依最終使用者劃分

  • 摘要
  • 醫院
  • 透析中心
  • 其他

第六章慢性腎臟病治療市場：依地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 澳大利亞
    • 印度
    • 韓國
    • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他領域

第七章競爭態勢

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022 年主要公司的定位

第八章公司簡介

  • AstraZeneca plc
  • Pfizer Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • B. Braun SE
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Fresenius SE and Co. KGaA
Product Code: A107121

According to a new report published by Allied Market Research, titled, "Chronic kidney disease treatment Market," The chronic kidney disease treatment market was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.

Chronic kidney disease treatment Market - IMG1

Chronic Kidney Disease (CKD) treatment refers to a range of medical interventions and strategies aimed at managing and slowing the progression of kidney damage and its associated complications. CKD is a progressive condition where the kidneys gradually lose their ability to filter waste products and excess fluids from the blood. The goals of CKD treatment include preserving kidney function, controlling symptoms, preventing or managing complications, and improving the overall quality of life for individuals with CKD.

Treatment approaches may include lifestyle modifications (such as dietary changes and regular physical activity), medications to control blood pressure and manage underlying conditions, interventions to address complications like anemia or bone disease, and in advanced stages, renal replacement therapies such as dialysis or kidney transplantation. The treatment plan is tailored to the individual's stage of CKD, underlying causes, comorbidities, and overall health status. Regular monitoring, close collaboration with healthcare providers, and adherence to the treatment plan are essential for optimizing outcomes and maintaining kidney health in individuals with CKD.

The increasing prevalence of CKD is a significant driver of the CKD treatment market. The global burden of CKD has been steadily rising due to various factors, including the aging population, the growing prevalence of risk factors such as diabetes and hypertension, and improved awareness and diagnosis. For instance, the aging population is a major contributing factor to the increasing prevalence of CKD. As people age, the risk of developing CKD tends to increase. According to the World Health Organization (WHO) in 2022, the global population aged 60 and above is expected to reach 2 billion by 2050, with a significant impact on the prevalence of age-related diseases, including CKD.

Furthermore, the rising incidence of risk factors like diabetes and hypertension has fueled the CKD epidemic. Diabetes, in particular, is a leading cause of CKD. The International Diabetes Federation in 2021, estimates that approximately 537 million adults were living with diabetes, and this number is projected to rise to 643 million by 2030 and 783 million by 2045. Thus, the prevailing cases, that directly translate to a higher risk of CKD development are anticipated to drive the market growth.

In addition, increase in alcohol consumption, rise in the number of diagnostic tests for kidney diseases, surge in obese population, rise in R&D activities for launch of novel drugs and improvement in the existing drugs, and emerging technology in developing economies are positively impacting the growth of the chronic kidney disease treatment market.

However, factors that hinder the market growth include the high cost of treatment for chronic kidney disease. Further, limited access to healthcare and inadequate healthcare infrastructure in certain regions can hinder the timely diagnosis and management of CKD. Thus, the aforementioned factors negatively impact market growth.

Moreover, the rise in the number of approvals from government regulatory agencies is creating lucrative opportunities for the CKD treatment market. For instance, in September 2022, AstraZeneca, a global leading life science company, received approval in China for Forxiga, to reduce the risk of sustained estimated glomerular filtration rate ((eGFR)) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D). In addition, the increase in investment in R&D activities increases the demand for efficient treatments, thereby providing lucrative opportunities for market growth.

The chronic kidney disease treatment market is segmented on the basis of treatment, end user, and region. On the basis of treatment, the market is classified into drugs and dialysis. The drugs is further categories into ACE Inhibitors, Erythropoietic Stimulating agents, Diuretics, and Other (phosphate binder, beta blockers, calcium channel blockers) and the dialiysis is further categorised into equipment and consumables. As per end user the market is segmented into Hospitals , Dialysis Centers and others (homecare and research and academic institutes). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global chronic kidney disease treatment market are AstraZeneca plc, Pfizer Inc. Johnson & Johnson, F. Hoffmann-La Roche Ltd., Baxter International Inc., Becton, Dickinson and Company, B. Braun SE, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Fresenius SE and Co. KGaA. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic kidney disease treatment market analysis from 2022 to 2032 to identify the prevailing chronic kidney disease treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the chronic kidney disease treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global chronic kidney disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End User

  • Hospital
  • Dialysis Center
  • Others

By Treatment

  • Drugs
    • Type
    • Erythropoietic Stimulating agents
    • Ace Inhibitors
    • Diuretics
    • Others
  • Dialysis
    • Type
    • Equipment
    • Consumables

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • Becton, Dickinson and Company
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca plc
    • B. Braun SE
    • AbbVie Inc.
    • Fresenius SE and Co. KGaA
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • Baxter International Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Technological advancement in chronic kidney disease treatment
      • 3.4.1.2. Increase in prevalence of chronic kidney disease (CKD)
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of CKD treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Drugs
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Drugs Chronic kidney disease treatment Market by Type
  • 4.3. Dialysis
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Dialysis Chronic kidney disease treatment Market by Type

CHAPTER 5: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Dialysis Center
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Treatment
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Treatment
      • 6.2.4.1.3. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Treatment
      • 6.2.4.2.3. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Treatment
      • 6.2.4.3.3. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Treatment
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Treatment
      • 6.3.4.1.3. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Treatment
      • 6.3.4.2.3. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Treatment
      • 6.3.4.3.3. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Treatment
      • 6.3.4.4.3. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Treatment
      • 6.3.4.5.3. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Treatment
      • 6.3.4.6.3. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Treatment
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Treatment
      • 6.4.4.1.3. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Treatment
      • 6.4.4.2.3. Market size and forecast, by End User
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Treatment
      • 6.4.4.3.3. Market size and forecast, by End User
      • 6.4.4.4. India
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Treatment
      • 6.4.4.4.3. Market size and forecast, by End User
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Treatment
      • 6.4.4.5.3. Market size and forecast, by End User
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Treatment
      • 6.4.4.6.3. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Treatment
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Treatment
      • 6.5.4.1.3. Market size and forecast, by End User
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Treatment
      • 6.5.4.2.3. Market size and forecast, by End User
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Treatment
      • 6.5.4.3.3. Market size and forecast, by End User
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Treatment
      • 6.5.4.4.3. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. AstraZeneca plc
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. Pfizer Inc.
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. Johnson & Johnson
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. F. Hoffmann-La Roche Ltd.
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Baxter International Inc.
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
  • 8.6. Becton, Dickinson and Company
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. B. Braun SE
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. AbbVie Inc.
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Teva Pharmaceutical Industries Ltd.
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Fresenius SE and Co. KGaA
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 02. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL DRUGS CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DIALYSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL DIALYSIS CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 07. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR HOSPITAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DIALYSIS CENTER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. U.S. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 15. U.S. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. CANADA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 17. CANADA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. UK CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 28. UK CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. ITALY CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 30. ITALY CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. JAPAN CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 39. JAPAN CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. CHINA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 41. CHINA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. AUSTRALIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 43. AUSTRALIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. INDIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 45. INDIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 51. LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. BRAZIL CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 54. BRAZIL CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. SAUDI ARABIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 56. SAUDI ARABIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. SOUTH AFRICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 58. SOUTH AFRICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. REST OF LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 60. REST OF LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 62. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 63. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 64. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 65. ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 66. PFIZER INC.: KEY EXECUTIVES
  • TABLE 67. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 68. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 69. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 70. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 71. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 72. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 73. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 74. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 75. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 76. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 77. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 78. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 79. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 80. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
  • TABLE 81. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 82. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 83. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 84. BECTON, DICKINSON AND COMPANY: PRODUCT SEGMENTS
  • TABLE 85. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 86. B. BRAUN SE: KEY EXECUTIVES
  • TABLE 87. B. BRAUN SE: COMPANY SNAPSHOT
  • TABLE 88. B. BRAUN SE: PRODUCT SEGMENTS
  • TABLE 89. B. BRAUN SE: PRODUCT PORTFOLIO
  • TABLE 90. B. BRAUN SE: KEY STRATERGIES
  • TABLE 91. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 92. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 93. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 94. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 95. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 96. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 99. FRESENIUS SE AND CO. KGAA: KEY EXECUTIVES
  • TABLE 100. FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
  • TABLE 101. FRESENIUS SE AND CO. KGAA: PRODUCT SEGMENTS
  • TABLE 102. FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 103. FRESENIUS SE AND CO. KGAA: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN CHRONIC KIDNEY DISEASE TREATMENT MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCHRONIC KIDNEY DISEASE TREATMENT MARKET
  • FIGURE 10. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DIALYSIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR HOSPITAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DIALYSIS CENTER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. CHRONIC KIDNEY DISEASE TREATMENT MARKET BY REGION, 2022
  • FIGURE 18. U.S. CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 19. CANADA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 20. MEXICO CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. GERMANY CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. FRANCE CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. UK CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. ITALY CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. SPAIN CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. REST OF EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. JAPAN CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CHINA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. AUSTRALIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. INDIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SOUTH KOREA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. BRAZIL CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SAUDI ARABIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH AFRICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 41. COMPETITIVE DASHBOARD
  • FIGURE 42. COMPETITIVE HEATMAP: CHRONIC KIDNEY DISEASE TREATMENT MARKET
  • FIGURE 43. TOP PLAYER POSITIONING, 2022
  • FIGURE 44. ASTRAZENECA PLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 45. ASTRAZENECA PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 46. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 47. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. BECTON, DICKINSON AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. B. BRAUN SE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. B. BRAUN SE: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. B. BRAUN SE: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 70. FRESENIUS SE AND CO. KGAA: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 71. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 72. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY REGION, 2021 (%)